GlassScriptPhysician profile
Emily K Bendlin
NPI 1902246747
$1,471.66
in general payments reported to CMS, 2019-2025
31 companies · $146 in 2025
The $146 reported for 2025 was more than what a typical Pediatrics provider received nationally (typical 2025 total: $96.93).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $266 · 2020: $195 · 2021: $501 · 2022: $210 · 2023: $87.49 · 2024: $66.57 · 2025: $146.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $300.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $300.42 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novo Nordisk INC | $266.44 | 2019-2025 | Rybelsus, Ozempic |
| Amarin Pharma, INC. | $164.49 | 2019-2021 | |
| Amgen INC. | $125.25 | 2019-2024 | Repatha |
| Pfizer INC. | $106.44 | 2021-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $84.94 | 2020-2024 | |
| Sanofi Pasteur INC. | $69.55 | 2019-2024 | |
| Boston Scientific Corporation | $50.25 | 2019-2022 | |
| Merck Sharp & Dohme LLC | $49.85 | 2020-2023 | Gardasil 9, Vaxneuvance, Vaxelis |
| Supernus Pharmaceuticals, INC. | $47.96 | 2022 | |
| Sobi, INC | $43.47 | 2019-2021 | |
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $41.15 | 2025 | Caplyta |
| Jazz Pharmaceuticals INC. | $36.07 | 2021 | |
| Genentech USA, INC. | $35.23 | 2019-2021 | |
| Abbvie INC. | $31.59 | 2021 | |
| Alk-Abello, INC | $29.73 | 2021-2022 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ultragenyx Pharmaceutical INC. | $28.96 | 2021-2022 | |
| Eisai INC. | $25.18 | 2019 | |
| Lilly USA, LLC | $24.11 | 2019-2021 | |
| Biohaven Pharmaceutical Holding Company LTD. | $23.13 | 2022 | |
| Therapeuticsmd, INC. | $22.62 | 2020 | |
| Insulet Corporation | $19.50 | 2021 | |
| Exeltis, USA INC. | $16.81 | 2021 | |
| Organon LLC | $16.51 | 2025 | Nexplanon |
| Axsome Therapeutics, INC. | $15.92 | 2025 | Symbravo |
| Adlon Therapeutics L.P. | $14.89 | 2021 | |
| Shire North American Group INC | $14.53 | 2019 | |
| Nestle Healthcare Nutrition INC. | $14.29 | 2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.23 | 2021 | |
| Teva Pharmaceuticals USA, INC. | $14.21 | 2022 | |
| Glaxosmithkline, LLC. | $13.15 | 2023 | Arexvy, Shingrix |
| Mayne Pharma Commercial LLC | $11.21 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Emily Bendlin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.